Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress

ROCKVILLE, Maryland, May 10, 2010 - Neuralstem, Inc. (NYSE Amex: CUR) CEO and President, Richard Garr, has
been invited to present at the Fifth Annual World Stem Cells and Regenerative
Medicine Congress, held May 11-13, in London, UK
www.terrapinn.com/2010/stemcells/index.stm. Neuralstem is currently in
a Phase I clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou
Gehrig's disease) with its spinal cord stem cells.

(Logo: www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

Mr. Garr's talk, at 2:30 on Wednesday, May 12, is entitled "Goals,
Challenges and Solutions for Bringing Cell-Based ALS Therapy to the Clinic."
It will address the goals and scientific potential of applying cell therapy
to ALS, as well as the challenges and solutions in bringing this treatment to
patients.

About Neuralstem, Inc.

Neuralstem's patented technology enables, for the first time, the ability
to produce neural stem cells of the human brain and spinal cord in commercial
quantities, and the ability to control the differentiation of these cells
into mature, physiologically relevant human neurons and glia. The company is
targeting major central nervous system diseases including: Ischemic Spastic
Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's
disease. ALS is a progressive fatal neurodegenerative disease that affects
nerve cells in the brain, leading to the degeneration and death of the motor
neurons in the spinal cord that control muscle movement. Neuralstem is in a
Phase I clinical trial to treat ALS. For more information, please go to
www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. Investors are cautioned that such forward-looking statements in this
press release regarding potential applications of Neuralstem's technologies
constitute forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development and
commercialization of potential products, uncertainty of clinical trial
results or regulatory approvals or clearances, need for future capital,
dependence upon collaborators and maintenance of our intellectual property
rights. Actual results may differ materially from the results anticipated in
these forward- looking statements. Additional information on potential
factors that could affect our results and other risks and uncertainties are
detailed from time to time in Neuralstem's periodic reports, including the
annual report on Form 10-K for the year ended December 31, 2009.

Richard Garr, President, +1-301-366-4960, or Meg McElroy, Shareholder Relations, +1-301-366-4960, or Deanne Eagle, Planet Communications, Media, +1-917-837-5866